You are here: Home > Projects and Research lines > HDAC inhibitors in hepatocellular carcinoma
Projects and Research lines
HDAC inhibitors in hepatocellular carcinoma

Mount Sinai School of Medicine In-house Grant

Previous evidence suggests that the modification of the methylation status and histone deacetylases (HDAC) in cancer cells has positive anti-tumoral effects. This study will evaluate the role of HDAC inhibitors in experimental models of HCC, as a proof-of-principle to conduct early clinical trials in humans.

Translational research in liver cancer

Liver Cancer Translational Research Laboratory

BCLC-IDIBAPS, Liver Unit, Hospital Clínic · Esther Koplowitz Center, 3rd Floor
Rosselló 153 · 08036 Barcelona · Tel: +34 93 227 9155

© Liver Cancer Translational Research Laboratory - IDIBAPS 2011 - 2017